Sweden
· Delayed Price · Currency is SEK Abera Bioscience AB Statistics
Total Valuation
Abera Bioscience AB has a market cap or net worth of SEK 54.96 million. The enterprise value is 51.86 million.
| Market Cap | 54.96M |
| Enterprise Value | 51.86M |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Abera Bioscience AB has 14.46 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 14.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.45% |
| Owned by Institutions (%) | n/a |
| Float | 12.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.95 |
| EV / Sales | 4.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.08 |
Financial Position
The company has a current ratio of 5.55
| Current Ratio | 5.55 |
| Quick Ratio | 2.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,244.57 |
Financial Efficiency
Return on equity (ROE) is -44.78% and return on invested capital (ROIC) is -29.50%.
| Return on Equity (ROE) | -44.78% |
| Return on Assets (ROA) | -24.21% |
| Return on Capital (ROIC) | -29.50% |
| Revenue Per Employee | 2.10M |
| Profits Per Employee | -619,669 |
| Employee Count | 6 |
| Asset Turnover | 1.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -21.06% |
| 50-Day Moving Average | 4.01 |
| 200-Day Moving Average | 4.58 |
| Relative Strength Index (RSI) | 43.95 |
| Average Volume (20 Days) | 13,914 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Abera Bioscience AB had revenue of SEK 12.60 million and -3.72 million in losses.
| Revenue | 12.60M |
| Gross Profit | 12.60M |
| Operating Income | -3.92M |
| Pretax Income | -3.72M |
| Net Income | -3.72M |
| EBITDA | n/a |
| EBIT | -3.92M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
| Cash & Cash Equivalents | 3.11M |
| Total Debt | n/a |
| Net Cash | 3.11M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 8.52M |
| Book Value Per Share | n/a |
| Working Capital | 6.23M |
Cash Flow
In the last 12 months, operating cash flow was -8.09 million and capital expenditures -445,000, giving a free cash flow of -8.53 million.
| Operating Cash Flow | -8.09M |
| Capital Expenditures | -445,000 |
| Free Cash Flow | -8.53M |
| FCF Per Share | -0.59 |
Margins
Gross margin is 100.00%, with operating and profit margins of -31.10% and -29.50%.
| Gross Margin | 100.00% |
| Operating Margin | -31.10% |
| Pretax Margin | -29.50% |
| Profit Margin | -29.50% |
| EBITDA Margin | n/a |
| EBIT Margin | -31.10% |
| FCF Margin | -67.68% |
Dividends & Yields
Abera Bioscience AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -15.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |